Relevance of cytokine production to infected pancreatic necrosis.
The purpose of this study was to evaluate the role of cytokines in septic conditions following acute pancreatitis and to elaborate a new strategy in the treatment. Increased TNF and IL-6 serum levels were found in 30% of the patients (n = 40), while the IL-6 level was elevated in all of them. There was a positive correlation between the serum IL-6 and sICAM-1 levels. The in vitro TNF and IL-6 producing capacities were initially higher in the study group, but decreased on subsequent days, especially in fatal cases (n = 3). Administration of pentoxifylline [PTX] (400 mg/day) to septic patients following necrotizing pancreatitis resulted in TNF and IL-6 production similar to that observed in control donors. The level of sICAM-1 also decreased following PTX therapy. These results suggest that cytokines produced by activated leucocytes are important in the pathogenesis of infected pancreatic necrosis, and their inhibition might be of therapeutic advantage.
Farkas
G
G
Department of Surgery, Albert Szent-Györgyi Medical University, Szeged, Hungary.
Nagy
Z
Z
Márton
J
J
Mándi
Y
Y
D018806:APACHE; D002423:Cause of Death; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007962:Leukocytes / Q000378:metabolism; D019283:Pancreatitis, Acute Necrotizing / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy / Q000276:immunology; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D016207:Cytokines; D015850:Interleukin-6; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D014665:Vasodilator Agents; D018799:Intercellular Adhesion Molecule-1; D010431:Pentoxifylline